Douglas S. Ingram, JD
Chief Executive Officer

Douglas S. Ingram, Chief Executive Officer, brings 20 years of biotech, pharmaceutical and medical device leadership to Chase. Most recently and until its acquisition by Actavis in early 2015, he was President of Allergan, a global pharmaceutical company with franchises in Neuroscience, Urology, Ophthalmology and Medical Aesthetics. Previously, Mr. Ingram was President of Allergan’s operations in Europe, the Middle East, and Africa. Earlier at Allergan he was responsible for building and leading numerous aspects of the global organization including Legal Affairs, Regulatory Affairs and Pharmacovigilance, Information Technology, Public Relations and External Communication, Human Resources and Audit and Compliance. In addition to Chase Pharmaceuticals, Mr. Ingram is a board member of Endo International plc, Pacific Life Insurance Company and Nemus Biosciences. He received his Bachelor of Science Degree, Magna Cum Laude, from Arizona State University, and his Juris Doctorate, Summa Cum Laude and Order of the Coif, from the James E. Rogers College of Law, University of Arizona.

Thomas N. Chase, MD
Chief Scientific Officer

Thomas N. Chase, MD, co-founder of Chase Pharmaceuticals and Chief Scientific Officer, served as the company’s first President and Chief Executive Officer. He is a globally recognized thought leader in neurodegenerative disorders and their treatment, with a focus on the pathogenesis and treatment of Alzheimer’s disease, Parkinson’s disease and related disorders. Dr. Chase is the former Scientific Director and head of the Experimental Therapeutics Branch for the National Institute of Neurological Disorders and Stroke (NINDS). He received his MD from Yale University School of Medicine. Dr. Chase completed his neurology residency at Harvard Medical School and Mass General Hospital and his postdoctoral training in basic and clinical neuropharmacology at the National Institute of Mental Health. He has served as principal investigator on nearly 200 clinical trials, authored numerous patents and published over 500 peer-reviewed papers. Dr. Chase was the founding president of the American Society for Experimental NeuroTherapeutics (ASENT).

Kathleen Clarence-Smith, MD, PhD
Chief Medical Officer

Kathleen Clarence-Smith, MD, PhD, co-founder of Chase Pharmaceuticals and Chief Medical Officer, is a world leader in the development of pharmaceuticals to treat neurodegenerative disorders. As the head of CNS development at Sanofi, Hoffmann-La Roche and Otsuka, Dr. Clarence-Smith successfully developed, secured approval for and supported the launch of numerous important neurological treatments including Abilify® (aripiprazole), a $7 billion peak-year sales pharmaceutical used in the treatment of schizophrenia and bipolar disorder. Dr. Clarence-Smith received both her MD and PhD in Neuroscience at the University of Tours (France) and completed a post-doctoral fellowship at Johns Hopkins University School of Medicine in the Department of Pharmacology and Experimental Therapeutics, headed by Solomon Snyder, MD. She is a board certified neurologist, one of the founders and a past President of ASENT, and is a member of several scientific societies. She is the author of more than 100 peer-reviewed papers and more than 30 patents.
Scott Giacobello, CPA
Chief Financial Officer

Scott Giacobello, CPA, brings almost 25 years of experience in finance and accounting to Chase.  He is an accomplished executive with significant financial and operational expertise.  Most recently, and until its acquisition by Actavis in early 2015, Mr. Giacobello served as Vice President of Finance for Global Research & Development at Allergan, a global pharmaceutical company.  Mr. Giacobello's previous experience includes financial positions at the Black & Decker Corporation and Ernst & Young, LLP.  Mr. Giacobello also serves as the secretary to the Chase Pharmaceuticals Board of Directors. Mr. Giacobello holds a Bachelor of Business Administration in Accounting from the University of Notre Dame and is a Certified Public Accountant.

Gary Charbonneau, MS
Senior Vice President Regulatory Affairs & Operations

Mr. Charbonneau, MA, brings over 25 years of industry experience to Chase.  Mr. Charbonneau has spent much of his career in Regulatory Affairs and Quality Assurance. Immediately prior to joining Chase, he was the Vice President of International Regulatory Affairs at Allergan where he spent the last 11 years in several Global Regulatory Affairs leadership roles and was integral in building the Global Regulatory Affairs organization.  During his tenure at Allergan he worked within various therapeutic areas including ophthalmology, urology, dermatology, and neurology where he was involved with several FDA approvals including Botox indications, Ozurdex and Lumigan. Mr. Charbonneau built his career at Amgen, Roche Bioscience, and Novo Nordisk. Mr. Charbonneau received his Bachelor of Science degree in Biological Science from California Polytechnic State University, SLO and his Masters in Regulatory Science from the University of Southern California.